Investor's are waiting for trial news, and the reverse split is the price killer I expected. Tomorrow's the first presentation a representative from the company has made in a long time, however I doubt he'll be able to reveal any trial news that Novartis hasn't released. Perhaps he'll have other news, but right now the hearing trial is why most investors are in the stock, and Novartis is likely not to say anything until they know the drug can either advance in its current format, require other trial protocols, or they drop the drug.
I don't believe they'll drop the drug as long as the possibility of supplementing it still exists, and Novartis has the right of first refusal on that drug. Perhaps tomorrow's presentation will have something to say about that drug, but it's possible that Novartis controls that as well.
Gary
